An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. *

CinFina Pharma Begins Phase 1 Obesity Treatment Trial

On July 30, CinFina Pharma, a CinRx portfolio company dedicated to advancing a portfolio of high-impact treatment options for obesity and metabolic diseases, announced the initiation of the Phase 1 MAD clinical trial for CIN-110, a novel, highly selective PYY_3-36 analog for the treatment of obesity.

This Phase 1 MAD clinical trial aims to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of CIN-110 in adults with obesity. The initiation of this MAD trial follows the ongoing SAD study, where CIN-110 was well-tolerated with noteworthy reductions in caloric intake and body weight. The SAD study will be used to inform dosing decisions in the current MAD study.

“To date, CIN-110 has demonstrated very strong safety and pharmacokinetic profiles in its single dose study, as well as encouraging pharmacodynamic data,” said Mary Bond, MS, MBA, chief translational science officer of CinRx Pharma. “We are excited to see this promising asset advance into this next clinical assessment where we will gain an even greater understanding of its potential to provide a safe and effective obesity treatment option for physicians and their patients.”

As a potent and highly selective PYY_3-36 analog with an extended half-life, CIN-110 has the potential to be durable and well-tolerated without the significant nausea and emesis seen in previous attempts to develop PYY-focused therapies. PYY_3-36 is an endogenous hormone secreted from endocrine L-cells in the gut in response to food, particularly fat ingestion, acting as a selective agonist of the neuropeptide Y2 receptor (Y2R) and safely decreasing food intake by reducing appetite.

About CIN-110 Phase 1 MAD Study:

The multiple ascending dose (MAD) study is designed as a randomized, placebo-controlled clinical trial that will investigate the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of CIN-110 delivered subcutaneously (SC) in study subjects with obesity over 12 weeks. Trial participants are males and females, ages 18-55, with a body mass index between 30.0 and 44.9 kg/m2. The study is planned to include multiple cohorts, each with 12 subjects randomized in a 3:1 ratio to receive SC CIN-110 or a matched placebo, respectively.

*Inclusion in Pharma Fridays does not suggest an endorsement by Endocrine News or the Endocrine Society.